Materialise/$MTLS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Materialise
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.
- Ticker
- $MTLS
- Sector
- Software & Cloud Services
- Primary listing
- NASDAQ
- Employees
- 2,556
- Headquarters
- Leuven, Belgium
- Website
- www.materialise.com
Materialise Metrics
BasicAdvanced
$418M
30.64
$0.24
1.33
-
Price and volume
Market cap
$418M
Beta
1.33
52-week high
$8.82
52-week low
$4.78
Average daily volume
266K
Financial strength
Current ratio
2.515
Quick ratio
2.184
Long term debt to equity
0.244
Total debt to equity
0.278
Profitability
EBITDA (TTM)
28.057
Gross margin (TTM)
57.44%
Net profit margin (TTM)
4.64%
Operating margin (TTM)
3.40%
Effective tax rate (TTM)
-1.73%
Revenue per employee (TTM)
$123,110
Management effectiveness
Return on assets (TTM)
1.38%
Return on equity (TTM)
5.02%
Valuation
Price to earnings (TTM)
30.64
Price to revenue (TTM)
1.377
Price to book
1.63
Price to tangible book (TTM)
2.19
Price to free cash flow (TTM)
18.876
Free cash flow yield (TTM)
5.30%
Free cash flow per share (TTM)
0.383
Growth
Revenue change (TTM)
4.19%
Earnings per share change (TTM)
180.86%
3-year revenue growth (CAGR)
2.64%
10-year revenue growth (CAGR)
9.46%
3-year earnings per share growth (CAGR)
73.97%
10-year earnings per share growth (CAGR)
18.03%
What the Analysts think about Materialise
Analyst ratings (Buy, Hold, Sell) for Materialise stock.
Analyst projections of the future price of Materialise stock.
Bulls say / Bears say
Medical revenue grew 9.7% in the third quarter and nearly 10% over the first nine months, making it the clearest engine of growth. Its strong position gives Materialise a route to build on demand for personalised medical solutions. (Materialise)
Management raised its 2026 adjusted EBIT guidance in August to €12–14 million and reaffirmed it in October. That points to confidence in cost control and execution, even as the company steps up investment. (Materialise, Materialise)
Net cash reached €82.5 million at the end of September, up €11.7 million from year-end, despite share buybacks. This financial headroom supports investment in products and growth without relying solely on borrowing. (Materialise)
Software revenue fell 4% in the third quarter as industrial customers remained cautious and sales cycles lengthened. Ongoing investment in the new CO-AM platform adds costs before the weaker demand has turned around. (The Motley Fool)
Group adjusted EBIT fell to €2.5 million from €2.9 million a year earlier, while net profit declined to €1.4 million from €1.8 million. Revenue rose just 2.1% on a reported basis, showing that higher sales have not yet translated into stronger quarterly earnings. (Materialise)
Manufacturing remained loss-making, with adjusted EBITDA at negative €0.3 million in the third quarter. Even after excluding divestitures, revenue grew only 1.5%, as weaker prototyping demand continued to offset stronger aerospace and defence business. (Materialise, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Materialise Financial Performance
Revenues and expenses
Materialise Earnings Performance
Company profitability
Upcoming events
No upcoming events
Materialise News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.